Medicare Enrolled
Dr. Jotika Thompson, M.D.
Hematology & Oncology · Van Nuys, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Thompson from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Thompson?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Thompson
Dr. Jotika Thompson is a hematology & oncology specialist in Van Nuys, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Thompson performed 1,453 Medicare services across 484 unique beneficiaries.
Between the years covered by Open Payments, Dr. Thompson received a total of $23,871 from 86 pharmaceutical and/or device companies across 1089 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Thompson is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 45% volume in CA
$23,871 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,453
Medicare services
Top 45% in CA for hematology & oncology
484
Unique beneficiaries
$54
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~81 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
316 | $66 | $247 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
284 | $0 | $0 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
241 | $102 | $409 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
113 | $11 | $48 |
| Assessment of emotional or behavioral problems An evaluation to identify and understand emotional or behavioral issues. This process involves reviewing symptoms and behaviors to determine the nature of the concerns. |
77 | $4 | $17 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
74 | $26 | $101 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
72 | $119 | $465 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
70 | $69 | $272 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
61 | $145 | $565 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
55 | $0 | $1 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
42 | $58 | $225 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
28 | $100 | $374 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
20 | $102 | $548 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
12.9% high complexity
31.1% medium
56.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$23,871
Total received (2018-2024)
Avg $3,410/year across 7 years
Top 18% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
86
Companies
1,089
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$23,826 (99.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$45 (0.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,279
2023
$4,489
2022
$3,239
2021
$3,141
2020
$3,162
2019
$2,615
2018
$1,945
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$545
Janssen Biotech, Inc.
$365
PFIZER INC.
$348
Merck Sharp & Dohme LLC
$330
Eisai Inc.
$248
Incyte Corporation
$248
Celgene Corporation
$238
E.R. Squibb & Sons, L.L.C.
$208
Astellas Pharma US Inc
$198
Daiichi Sankyo Inc.
$166
Takeda Pharmaceuticals U.S.A., Inc.
$165
Novartis Pharmaceuticals Corporation
$159
Lilly USA, LLC
$116
ABBVIE INC.
$109
PUMA BIOTECHNOLOGY, INC.
$107
ARRAY BIOPHARMA INC
$105
Genentech USA, Inc.
$100
GlaxoSmithKline, LLC.
$93
EMD Serono, Inc.
$89
Deciphera Pharmaceuticals Inc.
$84
PharmaEssentia USA Corporation
$81
Ipsen Biopharmaceuticals, Inc
$80
Boehringer Ingelheim Pharmaceuticals, Inc.
$77
Gilead Sciences, Inc.
$77
Karyopharm Therapeutics Inc.
$73
Genmab U.S., Inc.
$72
Blueprint Medicines Corporation
$70
Agios Pharmaceuticals, Inc.
$68
Alexion Pharmaceuticals, Inc.
$58
Stemline Therapeutics Inc.
$57
SUN PHARMACEUTICAL INDUSTRIES INC.
$54
Bayer Healthcare Pharmaceuticals Inc.
$51
Exelixis Inc.
$46
GENZYME CORPORATION
$44
Regeneron Healthcare Solutions, Inc.
$38
TerSera Therapeutics LLC
$37
Mirati Therapeutics, Inc.
$35
TAIHO ONCOLOGY, INC.
$33
SpringWorks Therapeutics, Inc.
$26
SOBI, INC
$25
ImmunoGen, Inc.
$23
Kite Pharma, Inc.
$22
Sirtex Medical Inc
$21
BeiGene USA, Inc.
$20
Teva Pharmaceuticals USA, Inc.
$18
Pharmacosmos Therapeutics Inc.
$18
RECORDATI_RARE_DISEASES_INC.
$17
Cumberland Pharmaceuticals, Inc.
$16
Top 3 companies account for 23.8% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$1,428
Incyte Corporation
$1,288
Novartis Pharmaceuticals Corporation
$1,162
PFIZER INC.
$1,154
AstraZeneca Pharmaceuticals LP
$1,150
Genentech USA, Inc.
$872
Celgene Corporation
$837
Seagen Inc.
$748
Merck Sharp & Dohme LLC
$698
Amgen Inc.
$666
GENZYME CORPORATION
$650
Karyopharm Therapeutics Inc.
$643
Takeda Pharmaceuticals U.S.A., Inc.
$636
Janssen Biotech, Inc.
$616
Merck Sharp & Dohme Corporation
$576
Astellas Pharma US Inc
$571
Alexion Pharmaceuticals, Inc.
$566
Lilly USA, LLC
$546
Bayer HealthCare Pharmaceuticals Inc.
$511
Boehringer Ingelheim Pharmaceuticals, Inc.
$500
Eisai Inc.
$482
GlaxoSmithKline, LLC.
$445
Exelixis Inc.
$422
Ipsen Biopharmaceuticals, Inc
$393
Daiichi Sankyo Inc.
$392
EMD Serono, Inc.
$295
Rigel Pharmaceuticals, Inc.
$251
Gilead Sciences, Inc.
$226
Clovis Oncology, Inc.
$221
Kyowa Kirin, Inc.
$192
Pharmacyclics LLC, An AbbVie Company
$183
ABBVIE INC.
$173
PharmaEssentia USA Corporation
$173
Puma Biotechnology, Inc.
$171
Seattle Genetics, Inc.
$161
Teva Pharmaceuticals USA, Inc.
$159
AbbVie Inc.
$158
Genmab U.S., Inc.
$155
ARRAY BIOPHARMA INC
$154
Stemline Therapeutics Inc.
$147
Kite Pharma, Inc.
$146
BeiGene USA, Inc.
$132
JAZZ PHARMACEUTICALS INC.
$128
PUMA BIOTECHNOLOGY, INC.
$128
Sun Pharmaceutical Industries Inc.
$122
Blueprint Medicines Corporation
$118
TOLMAR Pharmaceuticals, Inc.
$115
TerSera Therapeutics LLC
$115
Deciphera Pharmaceuticals Inc.
$107
Regeneron Healthcare Solutions, Inc.
$103
EUSA Pharma (US) LLC
$102
Pharmacyclics LLC, an AbbVie Company
$97
Taiho Oncology, Inc.
$94
Myovant Sciences Inc.
$92
Bayer Healthcare Pharmaceuticals Inc.
$91
Foundation Medicine, Inc.
$89
Agios Pharmaceuticals, Inc.
$85
SOBI, INC
$83
MorphoSys, US Inc.
$80
Pharmacosmos Therapeutics Inc.
$70
Mirati Therapeutics, Inc.
$70
Dova Pharmaceuticals
$69
Heron Therapeutics, Inc.
$65
TAIHO ONCOLOGY, INC.
$60
ImmunoGen, Inc.
$56
Sirtex Medical Inc
$56
TESARO, Inc.
$55
SUN PHARMACEUTICAL INDUSTRIES INC.
$54
EISAI INC.
$52
G1 Therapeutics, Inc.
$44
Spectrum Pharmaceuticals Inc.
$42
AbbVie, Inc.
$42
Secura Bio, Inc.
$42
Global Blood Therapeutics, Inc.
$41
Lexicon Pharmaceuticals, Inc.
$39
CTI BioPharma Corp.
$29
SpringWorks Therapeutics, Inc.
$26
Novocure Inc.
$24
Sumitomo Pharma America, Inc.
$23
Tolmar, Inc.
$21
RECORDATI_RARE_DISEASES_INC.
$17
Shire North American Group Inc
$16
Cumberland Pharmaceuticals, Inc.
$16
GE HEALTHCARE
$15
Advanced Accelerator Applications
$15
Helsinn Therapeutics (U.S.), Inc.
$12
Top 3 companies account for 16.2% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · AYVAKIT · Avastin · BAVENCIO · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · BYNFEZIA PEN · Bavencio · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CINVANTI · COPIKTRA · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ENJAYMO · ERBITUX · ERLEADA · Elahere · Enhertu · Epkinly · Erleada · FARESTON · FOUNDATIONONE · FOUNDATIONONE CDX · FRUZAQLA · Fabhalta · Farydak · Folotyn · GAZYVA · GILOTRIF · Herceptin · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · INQOVI · INREBIC · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Oncology · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PYRUKYND · Padcev · Perjeta · Phesgo · Pomalyst · QINLOCK · REBLOZYL · ROLVEDON · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · Rubraca · SANCUSO · SANDOSTATIN · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYLVANT · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tavalisse · Tazverik · Trodelvy · Truxima · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · Vitrakvi · Vonjo · Vyloy · XALKORI · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
294
Per 100K population
3.0
County median income
$87,760
Nearest hospital
VALLEY PRESBYTERIAN HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Thompson is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement in the top 18% of CA peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Thompson experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Thompson performed 316 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Thompson receive payments from pharmaceutical companies?
Yes. Dr. Thompson received a total of $23,871 from 86 companies across 1,089 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Thompson's costs compare to other hematology & oncology specialists in Van Nuys?
Dr. Thompson's average Medicare payment per service is $54. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Thompson) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Van Nuys
Browse hematology & oncology specialists in Van Nuys ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology